Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

We examined the involvement of sphingosine kinase-1 (SphK1), which governs the ceramide/sphingosine-1-phosphate balance, in susceptibility to imatinib of either sensitive or resistant chronic ...

One pharmacist drew attention to a massive pricing disparity on a key cancer drug, and that disparity may help to explain why ...

School of Pharmacy & Technology Management, SVKM’S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India ...

Thus, polymorphism can affect the quality, safety, and efficacy of the drug products. (2) Imatinib is a drug used for certain types of cancer and is marketed as its mesylate salt. It is a tyrosine ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025• APEX trial enrollment in AdvSM patients complete; top-line results ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Melvin Mann, diagnosed with chronic myeloid leukemia in 1994, participated in a clinical trial for Imatinib that extended his life by 30 years.

Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development ------ John Adams, PhD Appointed Chief Scientific ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.